ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Duke University Suspends Two Clinical Trials After Journal Paper Questions Assay Validity

October 9, 2009

Walter Reed Oncologic Pharmacy Residency Program Has Openings

November 25, 1988

Broad Institute wins NIH grant for first national SNP genotyping center.

October 8, 2004

As Avastin Decision Nears, Patient Groups Split On PFS In Front Line Breast Cancer.

February 22, 2008

Implants Don’t Cause Cancer, Long-Term Study Finds

May 26, 2006

Holland, Leader Win $250,00 Milken Awards: Six Others Get $50,000 Prizes

December 9, 1988